Senior Postdoctoral Researcher
University of Geneva, Switzerland
Tel: +41 (0) 22 37 95 80
Tuberculosis, Ebola virus, clinical trials
My projects have encompassed a broad range of vaccine, adjuvant, and immunotherapy research using human clinical samples, in vivo NHP and murine models, in vitro techniques, and novel in silico analyses. I completed a Ph.D. at The University of Melbourne, based on the synthesis, and in vivo characterization of novel universal influenza A virus vaccines, as well as preclinical vaccine adjuvants. I then moved to industry (CSL, Australia), where I investigated novel adjuvant formulations, anti-cancer vaccines, and adjuvanted mAb-based immunotherapies for solid and haematological cancers in vivo. Additional post-doctoral research (CEA/Vaccine Research Institute, France) involved the development of high-parameter cytometric techniques (CyTOF) to characterize longitudinal B and T lymphocytes effector and memory responses after vaccination.
My current research at the W.H.O. Collaborating Centre for Vaccine Immunology (University of Geneva, Switzerland), comprises of both fundamental and clinical vaccino-immunology. The primary aim of the basic immunology project, conducted within the TBVAC2020 TBVI Tuberculosis Vaccine consortium, has been to identify dendritic cell-derived signals that enhance the induction of lung-homing T cell responses. The long-term goal of this project is to develop improved vaccine adjuvants for respiratory pathogens, namely Mycobacterium tuberculosis. Additionally, I analysed innate immune responses in a clinical trial testing rVSV-ZEBOV, as part of the EBOVAC Ebola vaccine consortium. This study focuses on vaccine-induced modulation of the innate immune response, including cytokines and circulating NK cells, as well as the development of functional assays with cell lines and human samples.
Profile page on publons